Reuters logo
BRIEF-Loxo Oncology reports completion of clinical trial enrollment for larotrectinib NDA primary efficacy analysis
February 21, 2017 / 12:05 PM / 7 months ago

BRIEF-Loxo Oncology reports completion of clinical trial enrollment for larotrectinib NDA primary efficacy analysis

Feb 21 (Reuters) - Loxo Oncology Inc:

* Loxo Oncology announces completion of clinical trial enrollment for larotrectinib nda primary efficacy analysis

* Loxo Oncology Inc - company expects to report top-line data for NDA dataset in second half of 2017

* Loxo Oncology- expects to submit a new drug application in late 2017 or early 2018, and European marketing authorisation application in 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below